One interesting and novel observation from our study was the enrichment of the “COVID-19 signalling pathway” by DCM treatment at 200 μM but not at 100 μM, which was characterised by altered expression of several associated genes, including TMPRSS2, ADAM17, and TLR2. The differences in transcriptome levels brought about by varying concentrations of DCM (200 μM and 100 μM) suggest the importance of an adequate dose of DCM for effective intervention of the Omicron virus infection. The gene discussed is ADAM17; the disease is COVID-19.